PURPOSE: The purpose of this retrospective analysis was to evaluate the emergence of second primary malignancies and the contribution of different causes of death to the outcome of patients with locoregionally advanced head and cancer receiving primary chemoradiotherapy. EXPERIMENTAL DESIGN: We studied 324 patients with stage IV squamous cell head and neck cancer who were enrolled on five consecutive multicenter Phase II studies of concurrent chemoradiotherapy. All of the regimens included concurrent 5-fluorouracil and hydroxyurea on an alternate week schedule with radiotherapy, either alone (FHX) or with cisplatin (C-FHX) or paclitaxel (T-FHX). The cumulative incidence of second primary tumors or death from any cause was estimated using methods of competing risk analysis. RESULTS: Median follow-up of surviving patients was 5.2 years (2-10.6 years). The 5-year overall survival and progression-free survival of the cohort were 46% and 65%, respectively. Causes of death and median time of occurrence were as follows: disease (n = 88; 1.5 years), treatment-associated acute or late complications (n = 30; 4 months), second primary tumors (n = 18; 3.5 years), comorbidities (n = 41; 1.9 years), and unknown (n = 20; 5.1 years). Predominant causes of death from comorbidities were cardiac and respiratory illnesses. Twenty-six patients (8%) developed a second primary tumor at a median time of 2.8 years (4 months to 10 years). The cumulative incidence of second primary tumors was 5%, 7%, and 13% at 3, 5, and 10 years, respectively. The most frequent site of second primaries was the lung (n = 13), followed by the esophagus (n = 3) and head and neck (n = 2) CONCLUSIONS: Patients with locoregionally advanced head and neck cancer treated with concurrent chemoradiotherapy are potentially curable but face significant risks of mortality from causes other than disease progression. Ameliorating toxicity, and implementing secondary screening and chemoprevention strategies are major goals in the management of head and neck cancer.
PURPOSE: The purpose of this retrospective analysis was to evaluate the emergence of second primary malignancies and the contribution of different causes of death to the outcome of patients with locoregionally advanced head and cancer receiving primary chemoradiotherapy. EXPERIMENTAL DESIGN: We studied 324 patients with stage IV squamous cell head and neck cancer who were enrolled on five consecutive multicenter Phase II studies of concurrent chemoradiotherapy. All of the regimens included concurrent 5-fluorouracil and hydroxyurea on an alternate week schedule with radiotherapy, either alone (FHX) or with cisplatin (C-FHX) or paclitaxel (T-FHX). The cumulative incidence of second primary tumors or death from any cause was estimated using methods of competing risk analysis. RESULTS: Median follow-up of surviving patients was 5.2 years (2-10.6 years). The 5-year overall survival and progression-free survival of the cohort were 46% and 65%, respectively. Causes of death and median time of occurrence were as follows: disease (n = 88; 1.5 years), treatment-associated acute or late complications (n = 30; 4 months), second primary tumors (n = 18; 3.5 years), comorbidities (n = 41; 1.9 years), and unknown (n = 20; 5.1 years). Predominant causes of death from comorbidities were cardiac and respiratory illnesses. Twenty-six patients (8%) developed a second primary tumor at a median time of 2.8 years (4 months to 10 years). The cumulative incidence of second primary tumors was 5%, 7%, and 13% at 3, 5, and 10 years, respectively. The most frequent site of second primaries was the lung (n = 13), followed by the esophagus (n = 3) and head and neck (n = 2) CONCLUSIONS:Patients with locoregionally advanced head and neck cancer treated with concurrent chemoradiotherapy are potentially curable but face significant risks of mortality from causes other than disease progression. Ameliorating toxicity, and implementing secondary screening and chemoprevention strategies are major goals in the management of head and neck cancer.
Authors: Dapeng Lei; Erich M Sturgis; Li-E Wang; Zhensheng Liu; Mark E Zafereo; Qingyi Wei; Guojun Li Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-05-25 Impact factor: 4.254
Authors: Hyunsoon Cho; Angela B Mariotto; Bhupinder S Mann; Carrie N Klabunde; Eric J Feuer Journal: Am J Epidemiol Date: 2013-07-03 Impact factor: 4.897
Authors: Loren K Mell; Hanjie Shen; Phuc Felix Nguyen-Tân; David I Rosenthal; Kaveh Zakeri; Lucas K Vitzthum; Steven J Frank; Peter B Schiff; Andy M Trotti; James A Bonner; Christopher U Jones; Sue S Yom; Wade L Thorstad; Stuart J Wong; George Shenouda; John A Ridge; Qiang E Zhang; Quynh-Thu Le Journal: Clin Cancer Res Date: 2019-08-16 Impact factor: 12.531
Authors: Suejung G Kim; Mysore S Veena; Saroj K Basak; Eugene Han; Tracey Tajima; David W Gjertson; Joshua Starr; Ofer Eidelman; Harvey B Pollard; Meera Srivastava; Eri S Srivatsan; Marilene B Wang Journal: Clin Cancer Res Date: 2011-08-05 Impact factor: 12.531
Authors: Jianming Wang; Scott M Lippman; J Jack Lee; Hushan Yang; Fadlo R Khuri; Edward Kim; Jie Lin; David W Chang; Reuben Lotan; Waun K Hong; Xifeng Wu Journal: Carcinogenesis Date: 2010-07-12 Impact factor: 4.944
Authors: Collin F Mulcahy; Abdallah S R Mohamed; Aasheesh Kanwar; Katherine A Hutcheson; Alokananda Ghosh; David Vock; Randal S Weber; Stephen Y Lai; Gary Brandon Gunn; Mark Zafereo; William H Morrison; Renata Ferrarotto; Adam S Garden; David I Rosenthal; Clifton D Fuller Journal: Head Neck Date: 2018-05-13 Impact factor: 3.147
Authors: Clayton B Hess; Dominique L Rash; Megan E Daly; D Gregory Farwell; John Bishop; Andrew T Vaughan; Machelle D Wilson; Allen M Chen Journal: JAMA Otolaryngol Head Neck Surg Date: 2014-04 Impact factor: 6.223
Authors: Dapeng Lei; Erich M Sturgis; Zhensheng Liu; Mark E Zafereo; Qingyi Wei; Guojun Li Journal: Carcinogenesis Date: 2009-12-02 Impact factor: 4.944